title: Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
abstract: Eighteen patients with squamous cell cancer of the cervix were treated with i.v. docetaxel 100 mg/m2 over 1 h every 21 days. No patient received prior chemotherapy, except as a radiation sensitizer. Median age was 42 years (range 30-58) and Zubrod performance status was 1 (0-2). Ten (59%) patients had prior surgery and 11 (65%) had prior radiation therapy. Sixteen patients were evaluable for response. Two patients had a partial response (13%; 95% CI 0-32%) and eight (50%; 95% CI 23-77%) had stable disease. Dose reduction to 75 mg/m2 was required in 10 patients and to 55 mg/m2 in one patient. Granulocytopenia was the major hematopoietic toxicity (31% grade 3 and 44% grade 4). Docetaxel is active in patients with squamous cell cancer of the cervix and may be tolerable at this dose schedule.
authors.affiliation: University of Texas MD Anderson Cancer Center, Section of Gynecologic Medical Oncology, Houston 77030-4095, USA.
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: C F
authors.initials: CF
authors.lastname: Verschraegen
authors.forename: T
authors.initials: T
authors.lastname: Levy
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: A
authors.initials: A
authors.lastname: Fishman
authors.forename: R S
authors.initials: RS
authors.lastname: Freedman
authors.forename: A
authors.initials: A
authors.lastname: Kaplan
authors.forename: D G
authors.initials: DG
authors.lastname: Kieback
authors.forename: R
authors.initials: R
authors.lastname: Mante
authors.forename: K
authors.initials: K
authors.lastname: Ende
authors.forename: M
authors.initials: M
authors.lastname: Steger
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D043823:Taxoids; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel